We assessed the clinical outcomes of patients with critical limb-threatening ischemia (CLTI) who underwent interwoven nitinol stent (Supera) implantation for significant stenoses of the femoropopliteal segment. In this retrospective cohort study, 116 consecutive patients with CLTI who were treated with Supera stents between September 2015 and March 2020 were included in this analysis. Primary endpoint analysis was completed for amputation-free survival, target lesion revascularization (TLR), and mortality. After a mean follow-up time of 3.4 years, 21 (18%) patients had undergone amputations, 3 (2.6%) died, and, overall, the amputation-free survival rate was 81%. TLR occurred in 21 (18%) patients, resulting in the freedom from target lesion revascularization of 82%. The average Wagner score for all patients was 2.8 ± 1.1. A subgroup analysis of 57 patients revealed a median ulcer size of 3.0 cm2 [1.65, 9.0], with complete healing for 45 patients by 20 months. The Wagner score of this subgroup decreased by an average of 3.4 ± .9 points. Supera stents can be used together with other endovascular therapies and are a safe and effective treatment modality for CLTI.
ShuJSantulliG. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379-381.
2.
HirschATHartmanLTownRJ, et al.National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13:209-215.
3.
KohnCGAlbertsMJPeacockWF, et al.Cost and inpatient burden of peripheral artery disease: findings from the National Inpatient Sample. Atherosclerosis. 2019;286:142-146.
4.
MahoneyEMWangKCohenDJ, et al.One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1:38-45.
5.
MurabitoJMEvansJCNietoK, et al.Prevalence and clinical correlates of peripheral arterial disease in the Framingham offspring study. Am Heart J. 2002;143:961-965.
6.
BradburyAWAdamDJBeardJD, et al.Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-1934.
7.
StoyioglouAJaffMR. Medical treatment of peripheral arterial disease: A camprehensive review. J Vasc Interv Radiol. 2004;15:1197-1207.
8.
Abu DabrhAMSteffenMWUndavalliC, et al.The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62:1642-1651.
9.
NorgrenLHiattWRDormandyJA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:5-67.
10.
KolteDKennedyKFShishehborMH, et al.Thirty-day readmissions after endovascular or surgical therapy for critical limb ischemia: analysis of the 2013 to 2014 Nationwide readmissions databases. Circulation. 2017;136:167-176.
11.
MartinezRAShnayderMParrecoJ, et al.Nationally representative readmission factors in patients with claudication and critical limb ischemia. Ann Vasc Surg. 2018;52:96-107.
12.
DuffSMafiliosMSBhounsuleP, et al.The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019;15:187-208.
13.
LumsdenABDaviesMGPedenEK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther. 2009;16:31-62.
14.
SlovutDPSullivanTM. Critical limb ischemia: medical and surgical management. Vasc Med. 2008;13:291.
15.
KudoTChandraFAAhnSS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg. 2005;41:423-425.
16.
RomitiMAlbersMBrochado-NetoFC, et al.Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975-981.
17.
Rocha-SinghKJJaffMJoyeJ, et al.Major adverse limb events and wound healing following infrapopliteal artery stent implantation in patients with critical limb ischemia: the XCELL trial. Catheter Cardiovasc Interv. 2012;80:1042-1051.
18.
ParkSHRhaSWChoiCU, et al.Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. Trials. 2014;15:355.
19.
SchulteKLPilgerESchellongS, et al.Primary self-expanding nitinol stenting vs balloon angioplasty with optional bailout stenting for the treatment of infrapopliteal artery disease in patients with severe intermittent claudication or critical limb ischemia (expand study). J Endovasc Ther. 2015;22:690-697.
20.
BishuKArmstrongEJ. Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag. 2015;11:387-395.
21.
MatsumuraJSYamanouchiDGoldsteinJA, et al.The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the protégé everflex nitinol stent system II (DURABILITY II). J Vasc Surg. 2013;58:73-81.
22.
DumantepeMSerenMFazlıogullariO, et al.Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results. Vascular. 2015;25:666-675.
23.
GarciaLJaffMRMetzgerC, et al.Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8:e000014.
24.
LeónLRDieterRSGaddCL, et al.Preliminary results of the initial United States experience with the Supera woven nitinol stent in the popliteal artery. J Vasc Surg. 2013;57:1014-1022.
25.
MustaphaJAKatzenBTNevilleRF, et al.Disease burden and clinical outcomes following initial diagnosis of critical limb ischemia in the medicare population. JACC Cardiovasc Interv. 2018;11:1011-1012.
26.
ZellerTTiefenbacherCSteinkampHJ, et al.Nitinol stent implantation in TASC a and B superficial femoral artery lesions: the femoral artery conformexx trial (FACT). J Endovasc Ther. 2008;15:390-398.
27.
KrankenbergHSchlüterMSteinkampHJ, et al.Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285-292.
28.
LairdJRKatzenBTScheinertD, et al.Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
29.
GarciaLARosenfieldKRMetzgerCD, et al.SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89:1259-1267.
30.
WernerMPaetzoldABanning-EichenseerU, et al.Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10:861-868.
31.
PalenaLMDiaz-SandovalLJSultatoE, et al.Feasibility and 1-Year outcomes of subintimal revascularization with supera® stenting of long femoropopliteal occlusions in critical limb ischemia: the “supersub” study. Catheter Cardiovasc Interv. 2017;89:910-920.
32.
GoltzJPRitterCOKellersmannR, et al.Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force. J Endovasc Ther. 2012;19:450-456.
33.
ArmstrongEJJeon-SlaughterHKahlonRS, et al.Comparative outcomes of supera interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the XLPAD registry. J Endovasc Ther. 2020;27:60-65.
34.
AhmedMWidatallaAMahadiSE, et al.Implementation of diabetic foot ulcer classification system for research purposes to predict lower extremity amputation. Int J Diabetes Dev Ctries. 2009;29:1-5.
35.
LindaFTatiannaGBondeS, et al.The WIfI system for threatened limbs. Wound Manag. 2019;8:1-4.
